Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
Liaw B, Tsao C, Seng S, Jun T, Gong Y, Galsky M, Oh W. Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer. The Oncologist 2022, 28: 366-e224. PMID: 36519763, PMCID: PMC10078918, DOI: 10.1093/oncolo/oyac224.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerProstate cancerMetastatic castration-resistant prostate cancer patientsImproved time to disease progressionDNA damage repair mutationsTime to disease progressionBlood RNA signatureOral platinum analoguePlatinum-based chemotherapyPhase II studySerum tissue inhibitorAssociated with platinum responseTissue-based biomarkersPeripheral blood samplesMCRPC patientsMedian PSABlood biomarker measurementsII studyPlatinum responseBlood-based biomarkersSPARC trialPlatinum analoguesTissue inhibitorDay 1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply